Wechselwirkungen · Eliquis
Eliquis 0.15 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 76
HOS-124501 · Präparat HOS-095863
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 µM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 µM) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 µM. Therefore, apixaban is not expected to alter the metabolic clearance of co- administered medicinal products that are metabolised by these enzymes. Apixaban is not a significant inhibitor of P-gp.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 16ffefb33e6d519cba43633097c6163d2f30c49f8580271e106105195df7d2d3 · Zeichen 5926–6519 im Abschnitt